An examination of the potential interaction between pharmaceutical companies and the U.S. Food and Drug Administration (FDA) to discuss future studies finds that one-quarter of recent new drug approvals occurred without any meeting, and when such meetings occurred, pharmaceutical companies did not comply with one-quarter of the recommendations made by the FDA regarding study design or primary outcome. The study was published in the November 26 issue of iJAMA/i. To ...Wednesday 26 November 2014
Research Examines FDA Influence on Design of Pivotal Drug Studies
An examination of the potential interaction between pharmaceutical companies and the U.S. Food and Drug Administration (FDA) to discuss future studies finds that one-quarter of recent new drug approvals occurred without any meeting, and when such meetings occurred, pharmaceutical companies did not comply with one-quarter of the recommendations made by the FDA regarding study design or primary outcome. The study was published in the November 26 issue of iJAMA/i. To ...
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment